Cabot (NYSE:CBT) Stock Price Up 6.7% – Still a Buy?

Cabot Corporation (NYSE:CBT)’s stock price traded up 6.7% on Thursday . The company traded as high as $92.90 and last traded at $93.3770. Approximately 16,907 shares were traded during trading, a decline of 96% from the average session volume of 464,908 shares. The stock had previously closed at $87.49.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Truist Financial started coverage on shares of Cabot in a research report on Monday, June 8th. They issued a “buy” rating and a $98.00 price target on the stock. Mizuho lifted their target price on shares of Cabot from $80.00 to $90.00 and gave the stock a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. boosted their target price on shares of Cabot from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Wednesday, May 13th. UBS Group upped their price target on shares of Cabot from $81.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Cabot in a research report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $85.80.

Cabot Trading Up 0.4%

The business has a 50 day moving average of $83.21 and a two-hundred day moving average of $75.73. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of 17.67, a P/E/G ratio of 12.24 and a beta of 0.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.96 and a current ratio of 1.45.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $1.61 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.14. The firm had revenue of $904.00 million during the quarter, compared to analysts’ expectations of $900.30 million. Cabot had a return on equity of 21.33% and a net margin of 7.97%.The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.90 earnings per share. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. Equities analysts predict that Cabot Corporation will post 6.34 EPS for the current year.

Cabot Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 29th were given a $0.4725 dividend. This represents a $1.89 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Friday, May 29th. This is an increase from Cabot’s previous quarterly dividend of $0.45. Cabot’s payout ratio is 35.73%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CBT. NewEdge Advisors LLC grew its holdings in shares of Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after buying an additional 947 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Cabot by 32.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after acquiring an additional 108,645 shares during the last quarter. Empowered Funds LLC lifted its position in Cabot by 102.6% in the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after acquiring an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cabot by 3.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after acquiring an additional 4,048 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the last quarter. Institutional investors and hedge funds own 93.18% of the company’s stock.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.